Background {#Sec1}
==========

Sepsis places an enormous burden on healthcare systems across the globe due to its high incidence, substantial costs of treatment, and high mortality rate \[[@CR1]\]. Patients with septic shock often develop respiratory failure, with as many as 80% requiring mechanical ventilation \[[@CR2]\]. Sepsis patients requiring mechanical ventilation are at high risk for ventilator-associated complications \[[@CR3], [@CR4]\] and have a mortality rate approaching 50% \[[@CR2], [@CR5]\]. Considering the high incidence and mortality rate associated with mechanical ventilation among patients with sepsis, there is a need to identify novel and pragmatic approaches to improve outcomes in patients with sepsis-associated respiratory failure.

The management of the partial pressure of arterial carbon dioxide (PaCO~2~) is a fundamental aspect of care in all mechanically ventilated patients. The conventional paradigm dictates that the mechanical ventilator should be adjusted to target a normal physiological PaCO~2~ range. However, data has shown that elevated PaCO~2~ in the setting of a lung-protective ventilation strategy (i.e., permissive hypercapnia) is well tolerated and may be associated with improved survival among mechanically ventilated patients with sepsis \[[@CR6]\]. In addition to the advantages of low stretch ventilation, preclinical data suggests hypercapnia may protect against systemic organ injury through attenuation of inflammation and free radical generation \[[@CR7], [@CR8]\]. The ubiquitous need to manage PaCO~2~, combined with data suggesting benefit associated with hypercapnia, suggests that PaCO~2~ could be a target to improve outcomes in this vulnerable patient population.

The aim of this systematic review is to collate the biomedical literature of (1) preclinical studies testing the effects of higher PaCO~2~ levels in the setting of sepsis and (2) clinical investigations testing the effects of hypercapnia on clinical outcomes in mechanically ventilated patients with sepsis. Our overarching hypothesis is that the majority of the studies will demonstrate a potential benefit of higher PaCO~2~ levels in sepsis. If the preponderance of data suggests hypercapnia attenuates sepsis-induced injury, then this report will provide scientific rationale for implementing high-quality interventional trials to test the effects of targeting elevated PaCO~2~ levels in mechanically ventilated patients with sepsis.

Methods/design {#Sec2}
==============

Protocol and registration {#Sec3}
-------------------------

This systematic review protocol was prepared according to the guidelines set forth in the Cochrane Handbook for the Systematic Reviews of Interventions \[[@CR9]\] and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 (Supplemental Material) \[[@CR10]\]. This protocol's PROSPERO registration number is CRD42018086703.

Search for and identification of studies {#Sec4}
----------------------------------------

We will search CENTRAL, PubMed, CINAHL, and EMBASE using the following search terms: "hypoventilation" or "hypercapnia" or "hypercarbia" or "carbon dioxide" or "CO2" AND "bacterial infection" or "pneumonia" or "sepsis" or "septic shock" or "bacteremia." We modeled our search terms after search terms used in previously published systematic reviews \[[@CR11], [@CR12]\]. We will also screen reference lists of the articles we select for inclusion to identify additional studies for potential inclusion.

Eligibility criteria {#Sec5}
--------------------

We will include all study designs of the effects of hypercapnia in sepsis, severe sepsis, or septic shock. If a study population does not meet the inclusion criteria but a clearly defined subset of patients meets the inclusion criteria, the study may be included; however, only data pertaining to that subset of patients will be collected. The inclusion criteria for preclinical studies are as follows: (1) sepsis model (e.g., cecal ligation), (2) documented measurement of PaCO~2~, and (3) comparison of outcome measure between different PaCO~2~ levels. The inclusion criteria for clinical studies are as follows: (1) patients diagnosed with sepsis (including severe sepsis and septic shock; given we will be including paper regardless of date of publication and the variation in sepsis definitions over time, we will include any papers in which patients are diagnosed with an infection and have some definition of systemic involvement), (2) patients receiving invasive mechanical ventilation, (3) documented measurement of PaCO~2~, and (4) comparison of outcomes between different PaCO~2~ levels. We will consider studies eligible for review regardless of study design, language, or publication type. We will exclude studies that are secondary reports of studies already included. We also will exclude papers that are reviews, correspondence, or editorials; however, we will screen the reference lists of review articles to identify further studies for inclusion.

Study selection and data abstraction {#Sec6}
------------------------------------

Two independent reviewers will screen the titles and abstracts of identified studies for potential eligibility. After the relevance screen, the two reviewers will compare their exclusion logs and use the kappa statistic to quantify the inter-observer agreement. In cases of disagreement, the full text will be reviewed for inclusion. All studies deemed potentially relevant will be obtained and the full manuscripts will be reviewed for inclusion. Two reviewers will independently abstract data on all patient populations, interventions, outcome measures, adverse events, and results using a standardized data collection form.

Assessment of study bias {#Sec7}
------------------------

We will follow the Cochrane Handbook's recommendations for assessing risk of bias in clinical and non-clinical trials \[[@CR9]\]. For clinical trials, we will use the Cochrane Collaboration's tool which evaluates risk of bias in six domains: selection, performance, detection, attrition, reporting, and other biases \[[@CR9]\]. For observational human studies, we will use the New Castle-Ottawa Quality Assessment scale \[[@CR9]\]. For animal models, we will use the Systematic Review Centre for Laboratory Animal Experimentation's (SYRCLE) review of bias tool \[[@CR13]\]. The overall strength of the body of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) \[[@CR14]\].

Analysis {#Sec8}
--------

We will perform a primarily qualitative analysis of the data in accordance with the recommended methodology for qualitative reviews published in the Cochrane Handbook \[[@CR9]\]. We will first divide manuscripts into two groups: (1) preclinical and (2) clinical.

For preclinical studies, we will table the following: (1) animal model (e.g., mouse, pig); (2) study design (e.g., randomized control trial, prospective cohort); (3) mechanism for inducing sepsis (e.g., endotoxin); (4) PaCO~2~ categories; (5) outcome measures, including primary and all secondary outcomes; (6) effects of hypercapnia on outcome measures; and (7) study quality (defined above).

For clinical studies, we will table the following: (1) study design (e.g., cohort, randomized clinical trial); (2) study population (i.e., study inclusion criteria, age, and sepsis definition used); (3) PaCO~2~ categories; (4) outcome measures, including primary and all secondary outcomes; (5) effects of hypercapnia on outcome measures; and (6) study quality (defined above).

Protocol amendments {#Sec9}
-------------------

In the event of any changes to this protocol, each amendment will be stated, a date will be provided for each amendment, and the reasoning behind each amendment will be made known.

Discussion {#Sec10}
==========

Sepsis-associated respiratory failure is a common cause of morbidity and mortality, and its treatment requires an enormous amount of medical resources \[[@CR1], [@CR15]\]. New, cost-effective interventions are needed to address this disease process. Hypercapnia has been proposed to modulate gene expression, attenuate lung inflammation, and mitigate ventilator-associated lung injury, thereby potentially providing benefit to mechanically ventilated patients with sepsis \[[@CR16]--[@CR20]\]. To our knowledge, there is no systematic review of the world's literature on the effects of hypercapnia in the setting of sepsis.

This systematic review aims to synthesize the world's literature on the effects of hypercapnia in the setting of sepsis. We expect this systematic review will find that the majority of the studies will demonstrate a potential benefit of higher PaCO~2~ levels in sepsis. The results of this systematic review will contribute to the understanding of the effects of hypercapnia in the setting of sepsis and promote future research of PaCO~2~ management in mechanically ventilated patients with sepsis.
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